Media and Events

Upcoming · 24 Nov 2026DNB Nordic Healthcare Conference 2026Oslo, Norway
Upcoming · Date to be announcedNordnet interviewA link will be posted when available
Past eventsSITC 2026, ESMO 2026, ASGCT 2026 and moreSee all events →

Latest news

Cell Therapies Can “Cure” Cancers

Cell therapies have delivered “cures” in certain late-stage cancer patients with multiple approved treatments mainly for liquid cancers. Several cell therapy products have been approved by regulatory authorities with data from fewer than 100 patients.

Solid Cancers remain a major challenge

Whilst there has been progress, successes in liquid cancers have not translated into solid cancers, which represent by far the largest cancer burden and remain an unsolved challenge.

Zelluna targets Solid Cancers

Zelluna is developing a unique and proprietary TCR-NK cell therapy platform.
TCR-NK therapies are designed to overcome the current challenges of treating solid cancers and can potentially be used to treat a range of solid cancers with unmet medical need in high value markets.

Cell culture work in a laboratory safety cabinet
About Zelluna

Saving lives through innovative targeted cancer therapies

Zelluna is a clinical stage company with a mission to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The team comprises experienced biotech entrepreneurs who have taken immuno-oncology projects from inception through to the clinic, supported by a highly experienced international board.